Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 433 participants.
Also called NCT01787396
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 433 participants
- Sponsor
- Registry
-
NCT01787396
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01787396. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2015-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Gemigliptin 50mg
- Intervention (Drug)
- Placebo(Metformin)
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo(Gemigliptin)
- Lead sponsor
- LG Life Sciences
Record details
- Record id
cardio:ct-nct01787396- Content hash
54b9c36aef9016bc7f2ff1ba67ea08a82e4d7ac2f2da92529cfc9c4bd9e2a843